Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medicure has announced that the FDA has granted the company's cardio-protective drug, MC-1, fast track designation as a treatment to reduce cardiac damage caused by a lack of blood to the heart.
Subscribe to our email newsletter
“The FDA’s Fast Track designation is a significant endorsement of the sizeable medical need for a product like MC-1,” commented Medicure’s president and CEO, Dr Albert Friesen. “The Fast Track designation provides us with the opportunity to expedite the development of MC-1 to commercialization.”
The application for fast track designation was submitted based on the demonstrated clinical efficacy and safety of MC-1 and the unmet medical need the drug addresses. The FDA identified coronary artery disease requiring intervention as a life-threatening disease, and the need for a drug to treat heart attacks and strokes as the rationale for designating MC-1 as a fast track product.
Fast Track designated drugs are eligible for priority review (6 months versus the average 12 months) and/or the review of portions of the marketing application prior to the completion of the final registration package.